Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain (Q34785937)

4 August 2017

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain (English)

1 reference

4 August 2017

0 references

0 references

chronic neuropathic pain

0 references

botulinum toxin type A

1 reference

Danièle Ranoux

1

1 reference

4 August 2017

Nadine Attal

series ordinal

2

1 reference

4 August 2017

Francoise Morain

series ordinal

3

1 reference

4 August 2017

D Bouhassira

series ordinal

4

1 reference

4 August 2017

1 September 2008

1 reference

4 August 2017

1 reference

4 August 2017

64

1 reference

4 August 2017

274-283

1 reference

4 August 2017

3

1 reference

Clinical value of botulinum toxin in neurological indications

4 August 2017

1 reference

Botulinum toxin A for axillary hyperhidrosis (excessive sweating).

21 January 2018

1 reference

Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

21 January 2018

1 reference

Neurobiological basis for the use of botulinum toxin in pain therapy

21 January 2018

1 reference

Identification of the major steps in botulinum toxin action

21 January 2018

1 reference

Upregulation of calcitonin gene-related peptide at mouse motor nerve terminals poisoned with botulinum type-A toxin

21 January 2018

1 reference

Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy

21 January 2018

1 reference

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

21 January 2018

1 reference

Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity

21 January 2018

1 reference

Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice.

21 January 2018

1 reference

Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain

21 January 2018

1 reference

The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain

21 January 2018

1 reference

Chronic hyperalgesia and skin warming caused by sensitized C nociceptors.

21 January 2018

1 reference

Postherpetic neuralgia: irritable nociceptors and deafferentation

21 January 2018

1 reference

Epidemiology and treatment of neuropathic pain: the UK primary care perspective

21 January 2018

1 reference

Persistent postsurgical pain: risk factors and prevention

21 January 2018

1 reference

EFNS guidelines on pharmacological treatment of neuropathic pain.

21 January 2018

1 reference

Algorithm for neuropathic pain treatment: an evidence based proposal.

21 January 2018

1 reference

Analgesic therapy in postherpetic neuralgia: a quantitative systematic review

21 January 2018

1 reference

A focused review on the use of botulinum toxins for neuropathic pain

21 January 2018

1 reference

Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia

21 January 2018

1 reference

Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia.

21 January 2018

1 reference

The hospital anxiety and depression scale

21 January 2018

1 reference

Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin

21 January 2018

1 reference

Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin.

21 January 2018

1 reference

A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model

21 January 2018

1 reference

SV2 is the protein receptor for botulinum neurotoxin A.

21 January 2018

1 reference

The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey

21 January 2018

1 reference

The impact of neuropathic pain on health-related quality of life: review and implications

21 January 2018

1 reference

Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community.

21 January 2018

1 reference

Pharmacologic management of neuropathic pain: evidence-based recommendations

21 January 2018

1 reference

Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.21427

1 reference

4 August 2017

1 reference